CD47 and neoplasm: The IAP inhibitor birinapant makes tumor cells more sensitive to CL-derived TNF killing, while TNF is elevated after PD-1 blockade, and the combination of the two further enhances the efficacy of anti-PD-1 antibody therapy.156